BRPI0512891A - composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano - Google Patents
composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humanoInfo
- Publication number
- BRPI0512891A BRPI0512891A BRPI0512891-9A BRPI0512891A BRPI0512891A BR PI0512891 A BRPI0512891 A BR PI0512891A BR PI0512891 A BRPI0512891 A BR PI0512891A BR PI0512891 A BRPI0512891 A BR PI0512891A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- inhibiting
- methods
- solvate
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
COMPOSTO E UM SAL OU PRó-DROGA OU SOLVATO FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO, MéTODOS DE INIBIR A QUINASE 1 DO PONTO DE VERIFICAçãO EM UMA CéLULA, DE SENSIBILIZAR CéLULAS EM UM INDIVìDUO QUE PASSA POR UM TRATAMENTO QUIMIOTERAPêUTICO OU RADIOTERAPêUTICO PARA UMA CONDIçãO MéDICA E DE INIBIR A PROLIFERAçãO DE CéLULA ABERRANTE, USO DE UM COMPOSTO, E, ARTIGO DE FABRICAçãO PARA O USO FARMACêUTICO EM HUMANO Compostos de uréia substituídos úteis no tratamento de doenças e condições relacionadas com o dano ao DNA ou lesões na replicação do DNA são divulgados. Métodos de fabricar os compostos e seu uso como agentes terapêuticos, por exemplo, no tratamento de câncer e outras doenças caracterizadas pelos defeitos na replicação do DNA, segregação de cromossoma ou divisão celular também são divulgados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58529204P | 2004-07-02 | 2004-07-02 | |
PCT/US2005/023554 WO2006014359A2 (en) | 2004-07-02 | 2005-07-01 | Compounds useful for inhibiting chk1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0512891A true BRPI0512891A (pt) | 2008-04-15 |
Family
ID=35515699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512891-9A BRPI0512891A (pt) | 2004-07-02 | 2005-07-01 | composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano |
Country Status (10)
Country | Link |
---|---|
US (1) | US7560462B2 (pt) |
EP (1) | EP1768977A2 (pt) |
JP (1) | JP2008505112A (pt) |
KR (1) | KR20070043996A (pt) |
CN (1) | CN101010316A (pt) |
AU (1) | AU2005270102A1 (pt) |
BR (1) | BRPI0512891A (pt) |
CA (1) | CA2573063A1 (pt) |
MX (1) | MX2007000265A (pt) |
WO (1) | WO2006014359A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
CN101115727A (zh) * | 2004-08-19 | 2008-01-30 | 艾科斯有限公司 | 用于抑制chk1的化合物 |
AU2005295167B2 (en) | 2004-10-20 | 2012-05-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
US20080076770A1 (en) * | 2006-09-25 | 2008-03-27 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
EP2190429B1 (en) * | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
BR112015025347A2 (pt) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN105272930B (zh) * | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
WO2017016523A1 (zh) * | 2015-07-30 | 2017-02-02 | 正大天晴药业集团股份有限公司 | 靶向idh2突变的抗肿瘤化合物及其使用方法 |
EP3411036B1 (en) | 2016-02-04 | 2021-12-29 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
MX2019011506A (es) | 2017-03-31 | 2019-11-01 | Seattle Genetics Inc | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01163723A (ja) * | 1987-12-21 | 1989-06-28 | Nippon Telegr & Teleph Corp <Ntt> | 有機非線形光学材料 |
CN1213022C (zh) * | 1997-12-22 | 2005-08-03 | 拜尔有限公司 | 用对称和不对称的取代二苯脲抑制raf激酶 |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
-
2005
- 2005-07-01 US US11/630,626 patent/US7560462B2/en not_active Expired - Fee Related
- 2005-07-01 KR KR1020077002555A patent/KR20070043996A/ko not_active Application Discontinuation
- 2005-07-01 MX MX2007000265A patent/MX2007000265A/es not_active Application Discontinuation
- 2005-07-01 WO PCT/US2005/023554 patent/WO2006014359A2/en active Application Filing
- 2005-07-01 JP JP2007519487A patent/JP2008505112A/ja active Pending
- 2005-07-01 BR BRPI0512891-9A patent/BRPI0512891A/pt not_active IP Right Cessation
- 2005-07-01 EP EP05791683A patent/EP1768977A2/en not_active Withdrawn
- 2005-07-01 CN CNA2005800294061A patent/CN101010316A/zh active Pending
- 2005-07-01 AU AU2005270102A patent/AU2005270102A1/en not_active Abandoned
- 2005-07-01 CA CA002573063A patent/CA2573063A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1768977A2 (en) | 2007-04-04 |
US20080214573A1 (en) | 2008-09-04 |
AU2005270102A1 (en) | 2006-02-09 |
CA2573063A1 (en) | 2006-02-09 |
MX2007000265A (es) | 2007-07-20 |
WO2006014359A3 (en) | 2007-01-11 |
CN101010316A (zh) | 2007-08-01 |
KR20070043996A (ko) | 2007-04-26 |
JP2008505112A (ja) | 2008-02-21 |
US7560462B2 (en) | 2009-07-14 |
WO2006014359A2 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0512891A (pt) | composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano | |
EP3356359B1 (en) | Inhibitors of kras g12c mutant proteins | |
Santo et al. | Targeting cyclin-dependent kinases and cell cycle progression in human cancers | |
US11976068B2 (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy | |
BRPI0514466A (pt) | composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante | |
Wang et al. | HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy | |
ES2826443T3 (es) | Inhibidores de proteínas mutantes KRAS G12C | |
WO2018064510A1 (en) | Inhibitors of kras g12c mutant proteins | |
WO2017058902A1 (en) | Inhibitors of kras g12c mutant proteins | |
WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
BRPI0517426A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente | |
BR112014015720A8 (pt) | derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases | |
ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
BRPI0515488A (pt) | derivados de heterocìclicos e seu uso como agentes terapêuticos | |
AU2020257159B2 (en) | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
BRPI0514310A (pt) | 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos | |
MX2007012116A (es) | Derivados de heteroaril urea utiles para inhibir chk1. | |
Chen et al. | The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome | |
BR112021013362A2 (pt) | Agentes rnai para inibição da expressão de hif-2 alfa (epas1), suas composições e métodos de uso | |
Qian et al. | The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak | |
D'costa et al. | CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells | |
BR0309988A (pt) | Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |